Fabiszewska, S.; Derda, E.; Szymanska, E.; Osiecki, M.; Kierkus, J.
Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases. J. Clin. Med. 2021, 10, 2997.
https://doi.org/10.3390/jcm10132997
AMA Style
Fabiszewska S, Derda E, Szymanska E, Osiecki M, Kierkus J.
Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases. Journal of Clinical Medicine. 2021; 10(13):2997.
https://doi.org/10.3390/jcm10132997
Chicago/Turabian Style
Fabiszewska, Sylwia, Edyta Derda, Edyta Szymanska, Marcin Osiecki, and Jaroslaw Kierkus.
2021. "Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases" Journal of Clinical Medicine 10, no. 13: 2997.
https://doi.org/10.3390/jcm10132997
APA Style
Fabiszewska, S., Derda, E., Szymanska, E., Osiecki, M., & Kierkus, J.
(2021). Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases. Journal of Clinical Medicine, 10(13), 2997.
https://doi.org/10.3390/jcm10132997